XOMA (NASDAQ:XOMA) Raised to “Hold” at ValuEngine

XOMA (NASDAQ:XOMA) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Tuesday, ValuEngine reports.

A number of other research analysts have also recently weighed in on XOMA. TheStreet raised shares of XOMA from a “d+” rating to a “c” rating in a research report on Tuesday, November 12th. HC Wainwright set a $30.00 price target on shares of XOMA and gave the company a “buy” rating in a research report on Friday, September 27th. Zacks Investment Research raised shares of XOMA from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Saturday, November 9th. Finally, Wedbush reaffirmed a “buy” rating and set a $25.00 price target on shares of XOMA in a research report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $26.33.

XOMA stock opened at $24.15 on Tuesday. XOMA has a 1 year low of $11.02 and a 1 year high of $26.90. The firm has a 50 day moving average price of $21.75 and a 200 day moving average price of $18.68. The company has a market cap of $214.20 million, a price-to-earnings ratio of -15.19 and a beta of 1.27. The company has a debt-to-equity ratio of 1.31, a quick ratio of 4.37 and a current ratio of 4.37.

XOMA (NASDAQ:XOMA) last released its earnings results on Tuesday, November 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.68. XOMA had a negative net margin of 10.19% and a negative return on equity of 8.93%. The firm had revenue of $8.86 million during the quarter. Sell-side analysts predict that XOMA will post -0.22 EPS for the current year.

In other news, CFO Thomas M. Burns sold 3,829 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $21.96, for a total transaction of $84,084.84. Following the transaction, the chief financial officer now directly owns 10,384 shares of the company’s stock, valued at $228,032.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO James R. Neal sold 3,830 shares of the business’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $21.96, for a total transaction of $84,106.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,459 shares of company stock worth $374,142. 9.89% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Stonepine Capital Management LLC lifted its position in shares of XOMA by 18.9% during the second quarter. Stonepine Capital Management LLC now owns 270,449 shares of the biotechnology company’s stock worth $4,019,000 after purchasing an additional 43,019 shares in the last quarter. RBF Capital LLC acquired a new position in shares of XOMA during the second quarter worth $1,479,000. Paloma Partners Management Co acquired a new position in shares of XOMA during the second quarter worth $510,000. Marshall Wace LLP acquired a new position in shares of XOMA during the second quarter worth $434,000. Finally, Morgan Stanley lifted its position in shares of XOMA by 2,151.6% during the second quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock worth $355,000 after purchasing an additional 22,828 shares in the last quarter. 37.20% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

Featured Article: Trading Ex-Dividend

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.